Sanofi (SNYNF) said new data from the HARMONIE Phase 3b trial showed an 83.21% reduction in hospitalizations due to RSV-related lower respiratory tract disease in infants under 12 months of age who received a single dose of nirsevimab, compared to infants who received no RSV intervention.